CJC-1295
CJC-1295 with Drug Affinity Complex (DAC)
Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pituitary growth hormone release. The DAC modification extends its half-life to approximately 6-8 days, allowing for less frequent dosing. It is widely used for anti-aging, fat loss, sleep improvement, and overall growth hormone optimization.
Mechanism of Action
CJC-1295 binds to GHRH receptors on the anterior pituitary, stimulating the synthesis and secretion of growth hormone (GH) in a pulsatile manner. The DAC linker binds to albumin in the bloodstream, dramatically extending the half-life. This results in sustained GH elevation without the supraphysiological spikes associated with exogenous GH administration.
Dosage Information
Typical Dose
1-2 mg per week
Frequency
1-2 times per week
Administration
Subcutaneous injection
Notes
Best results when combined with a GHRP such as Ipamorelin. Administer before bed to synergize with natural GH release during sleep. Cycle 8-12 weeks on, 4 weeks off.
Potential Side Effects
Research References
Community Experiences
No experiences shared yet. Be the first!
Stacking Compatibility
In These Stacks
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 1-2 mg per week
- Frequency
- 1-2 times per week
- References
- 2 studies